Latest Articles
Development of a senescence-related lncRNA signature in endometrial cancer based on multiple machine learning models - Frontiers
Development of a senescence-related lncRNA signature in endometrial cancer based on multiple machine learning models Frontiers
Published: Nov. 11, 2025, 4:15 p.m.
Integrative transcriptomic analysis identifies shared EndMT-related gene signatures in endometriosis and recurrent miscarriage - Nature
Integrative transcriptomic analysis identifies shared EndMT-related gene signatures in endometriosis and recurrent miscarriage Nature
Published: Oct. 21, 2025, 9:39 a.m.
Identification and Validation of Lactate-related gene signatures in endometriosis for clinical valuation and immune characterization by WGCNA and machine learning - Frontiers
Identification and Validation of Lactate-related gene signatures in endometriosis for clinical valuation and immune characterization by WGCNA and machine learning Frontiers
Published: Sept. 16, 2025, 6:06 p.m.
Petition calling for statutory menstruation leave hits over 60,000 signatures - The New Feminist
Petition calling for statutory menstruation leave hits over 60,000 signatures The New Feminist
Published: Aug. 31, 2025, 2:49 a.m.
A Lipid Metabolism and Lysosome-based Risk Signature for Prognosis and Immune Response Prediction in Uterine Corpus Endometrial Carcinoma - Frontiers
A Lipid Metabolism and Lysosome-based Risk Signature for Prognosis and Immune Response Prediction in Uterine Corpus Endometrial Carcinoma Frontiers
Published: Aug. 18, 2025, 5:24 p.m.
Characterizing disease-associated microbiome signatures using matched... - researchgate.net
Characterizing disease-associated microbiome signatures using matched... researchgate.net
Published: July 17, 2025, 7:18 p.m.
Schoolboy's bank holiday petition gains over 20,000 signatures - Yahoo
Schoolboy's bank holiday petition gains over 20,000 signatures Yahoo
Published: June 30, 2025, 3 p.m.
ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer - Pharmacy Times
ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer Pharmacy Times
Published: Feb. 10, 2025, 2:34 p.m.
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer OncLive
Published: Feb. 5, 2025, 5:17 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times
Published: Feb. 5, 2025, 1:07 p.m.
Link copied to clipboard!